Annual report 2011

Today Vitrolife is publishing the Annual Report for 2011 in Swedish. The Annual Report is attached to this press release and will also be available on www.vitrolife.com.

The printed version of the Annual Report will be distributed by mail during the week commencing 2 April. It will be distributed to Nordic shareholders who are new from last year and to remaining shareholders who have requested that the annual report should be sent to them.

The printed version of the Annual Report can be ordered on the company's website www.vitrolife.com, by phone +46 (0)31 721 80 00 or by email info@vitrolife.com.

Gothenburg, Sweden

March 26, 2012

VITROLIFE AB (publ)

Vitrolife is a global biotechnology/medical device Group that works in the areas of Fertility and Transplantation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes. The Transplantation product area works with solutions and systems for assessing and preserving organs outside the body, so as to be able to select usable organs and keep them in optimal condition pending transplantation.

Vitrolife today has approximately 220 employees and its products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

_________________________________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.

Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

Tags: